ProQR Therapeutics (NASDAQ: PRQR) Schedules Presentation at Citizens Life Sciences Conference

March 3, 2026

Expert Analysis ProQR Therapeutics (NASDAQ: PRQR) continues to reinforce its commitment to innovative RNA therapies by leveraging its proprietary ADAR-mediated Axiomer™ RNA editing platform. This technology shows promise for transformative treatments by selectively editing RNA to correct genetic disorders at the molecular level. The upcoming presentation demonstrates the company’s dedication to advancing both scientific discovery and investor communication in the biotech field. Engaging with stakeholders through high-profile conferences allows ProQR…

Read More >>